A pre-specific exploratory analysis of SURPASS-4 evaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in chronic kidney disease. Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands) discusses the outcome of the analysis and the impact of tirzepatide for clinical practice.
Professor Hiddo Heerspink presented an abstract entitled ‘Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4‘ at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- The SURPASS-4 study evaluated progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in a pre-specified exploratory analysis; what were these endpoints, and how do they relate to clinical practice? (0:24)
- What benefits were shown for treatment with tirzepatide versus daily insulin glargine? What efficacy outcomes were observed in people who were at high risk of cardiovascular disease? (1:46)
- How can tirzepatide optimize management of CKD in people with type 2 diabetes and potentially improve outcomes in practice? (3:39)
Disclosures: Hiddo Heerspink is a consultant for: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Janssen, NovoNordisk and Travere. Hiddo Heerspink has received grant/research support from AstraZeneca, Boehringer Ingelheim and Novo Nordisk and is a speaker’s bureau participant with AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
